Cancer Drug Co. Beats Investor Suit Over FDA Rejection
By Sydney Price · May 20, 2025, 9:25 PM EDT
Cancer drug company Checkpoint Therapeutics Inc. has permanently escaped a shareholder suit alleging it understated the likelihood the U.S. Food and Drug Administration would refuse approving Checkpoint's lead product candidate, with...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login